52273-78-6

Upstream product

• 1504-64-9 3-(3-nitrophenyl)prop-2-en-1-ol 
• 1664-54-6 3-(3-aminophenyl)propionic acid 
• 103606-71-9 3-(3-nitrophenyl)-2-propyn-1-ol 
• 645-00-1 m-iodonitrobenzene 
• 63307-44-8 3-(3-nitrophenyl)-1-propanol 
• 125872-97-1 ethyl (E)-3-(3-aminophenyl)acrylate 
• 1504-76-3 3-nitrocinnamaldehyde 

Downstream Products

• 162471-98-9 Isophthalic acid 1-{3-[3-(3-methoxycarbonyl-benzoylamino)-phenyl]-propyl} ester 3-methyl ester 
• 83101-15-9 3-(3-bromopropyl)cyanobenzene 
• 83101-17-1 γ-(3-Cyanphenyl)propylacetaminomalonsaeurediethylester 
• 83101-46-6 5-(3-Cyanphenyl)-2-tosylaminovaleriansaeureanilid 
• 83101-45-5 5-(3-Cyanphenyl)-2-tosylaminovaleriansaeuremorpholid 
• 83101-21-7 3-(4-Amino-4-carboxy-butyl)-benzoic acid; hydrochloride 
• 83101-19-3 2-Amino-5-(3-carbamoyl-phenyl)-pentanoic acid; hydrochloride 
• 83101-58-0 3-[5-Morpholin-4-yl-5-oxo-4-(toluene-4-sulfonylamino)-pentyl]-thiobenzamide 
• 83101-59-1 5-(3-Thiocarbamoyl-phenyl)-2-(toluene-4-sulfonylamino)-pentanoic acid phenylamide 
• 83101-50-2 5-(3-Cyanphenyl)-2-α-naphthylsulfonylaminovaleriansaeuremorpholid 
• 83101-54-6 5-(3-Cyanphenyl)-2-β-naphthylsulfonylaminovaleriansaeuremorpholid 
• 83101-63-7 3-[5-Morpholin-4-yl-4-(naphthalene-1-sulfonylamino)-5-oxo-pentyl]-thiobenzamide 
• 83101-67-1 3-[5-Morpholin-4-yl-4-(naphthalene-2-sulfonylamino)-5-oxo-pentyl]-thiobenzamide 
• 83101-84-2 3-[5-Morpholin-4-yl-5-oxo-4-(toluene-4-sulfonylamino)-pentyl]-benzamidine; hydriodide 

Relevant academic research and scientific papers

Optical Control of Mitosis with a Photoswitchable Eg5 Inhibitor

Eg5 is a kinesin motor protein that is responsible for bipolar spindle formation and plays a crucial role during mitosis. Loss of Eg5 function leads to the formation of monopolar spindles, followed by mitotic arrest, and subsequent cell death. Several cell-permeable small molecules have been reported to inhibit Eg5 and some have been evaluated as anticancer agents. We now describe the design, synthesis, and biological evaluation of photoswitchable variants with five different pharmacophores. Our lead compound Azo-EMD is a cell permeable azobenzene that inhibits Eg5 more potently in its light-induced cis form. This activity decreased the velocity of Eg5 in single-molecule assays, promoted formation of monopolar spindles, and led to mitotic arrest in a light dependent way.

MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

HALOETHYL UREA COMPOUNDS AND THEIR USE TO ATTENUATE, INHIBIT OR PREVENT NON-CANCEROUS PATHOGENIC CELLULAR PROLIFERATION AND DISEASES ASSOCIATED THEREWITH

The present invention provides haloethyl urea compounds as described in Formula (I) and their use as anti-proliferative agent in the attenuation, inhibition, or prevention of non-cancerous cellular proliferation. These compounds are also provided for use as a therapeutic agent in the treatment of a disease or disorder, wherein pathogenesis of said disease or disorder is associated with non-cancerous pathogenic cellular proliferation.

HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION

The present invention provides haloethyl urea compounds as described in Formula (I) and their use as therapeutic agent in the attenuation, inhibition, or prevention of cancer cell migration and cancer cell proliferation.

CYCLOPENTENE DERIVATIVES USEFUL AS ANTAGONISTS OF THE MOTILIN RECEPTOR

The compounds of formula I are useful in treating gastrointestinal disorders associated with antagonizing the motilin receptor disorders. The compounds compete with erythromycin and motilin for the motilin receptor. In addition the compounds are antagonists of the contractile smooth muscle response to those ligands.